Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Oncotelic Therapeutics's Total Assets for the quarter that ended in Mar. 2026 was $393.96 Mil.
During the past 12 months, Oncotelic Therapeutics's average Total Assets Growth Rate was 1381.40% per year.
During the past 3 years, the average Total Assets Growth Rate was 122.10% per year.
During the past 5 years, the average Total Assets Growth Rate was 50.90% per year.
During the past 10 years, the average Total Assets Growth Rate was 104.10% per year.
During the past 13 years, Oncotelic Therapeutics's highest 3-Year average Total Assets Growth Rate was 641.00%. The lowest was -47.50%. And the median was 6.85%.
Note:
The Net Income data used here is four times the quarterly (Mar. 2026) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
Oncotelic Therapeutics's Asset Turnover for the quarter that ended in Mar. 2026 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
Oncotelic Therapeutics Total Assets Related Terms
Oncotelic Therapeutics Total Assets Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
Oncotelic Therapeutics's Total Assets for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Oncotelic Therapeutics (OTLC) has a Total Assets of $393.96 Mil as of Mar. 2026. The total amount of assets as recorded on a company's balance sheet. View historical data on Oncotelic Therapeutics and its competitors.
Is Oncotelic Therapeutics' Total Assets too high?
Oncotelic Therapeutics' current Total Assets is $393.96 Mil.
How does Oncotelic Therapeutics' Total Assets compare to KTTA and LSTA?
Oncotelic Therapeutics' Total Assets of $393.96 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Assets for a Biotechnology company?
A good Total Assets depends on the Biotechnology industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Assets mean?
A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on Oncotelic Therapeutics and its competitors. Oncotelic Therapeutics's current Total Assets is $393.96 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oncotelic Therapeutics stock overvalued right now?
Oncotelic Therapeutics (OTLC) has a current Total Assets of $393.96 Mil. The current Total Assets is $393.96 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Assets calculated?
Total Assets is calculated from a company's financial statements. For Oncotelic Therapeutics (OTLC), the current Total Assets is $393.96 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Oncotelic Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing drugs for the treatment of orphan oncology indications, developing antisense and small molecule injectable drugs for the treatment of cancer. OT-101 is its flagship immuno-oncology drug candidate. OT-101 also has activity against SARS-CoV-2. Its other products under the pipeline are Artemisinin, CA4P, AL-101, and Oxi4503.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OTLC has been successfully added to your 
